Search
Search Results
-
Adequate antiviral treatment lowers overall complications of cytomegalovirus colitis among inpatients with inflammatory bowel diseases
BackgroundCytomegalovirus (CMV) colitis significantly complicates the course of inflammatory bowel disease (IBD), frequently leading to severe...
-
Functional cure is associated with younger age in children undergoing antiviral treatment for active chronic hepatitis B
Background and AimsFunctional cure is difficult to achieve using current antiviral therapies; moreover, limited data are available regarding...
-
Perceived Risk for Severe COVID-19 and Oral Antiviral Use Among Antiviral-Eligible US Adults
IntroductionOral antiviral medications are important tools for preventing severe COVID-19 outcomes. However, their uptake remains low for reasons...
-
Assessing antiviral treatment efficacy and risk factors for severe COVID-19 in kidney transplant recipients during the Omicron subvariant-dominant period: a retrospective study
BackgroundKidney transplant recipients (KTRs) are at risk of severe coronavirus disease 2019 (COVID-19), and even now that Omicron subvariants have...
-
Could widespread use of antiviral treatment curb the COVID-19 pandemic? A modeling study
BackgroundDespite the development of safe and effective vaccines, effective treatments for COVID-19 disease are still urgently needed. Several...
-
Incidence and antiviral treatment of cytomegalovirus infection in infants with biliary atresia
PurposePatients with biliary atresia (BA) and cytomegalovirus (CMV) infection may have poorer outcomes after Kasai portoenterostomy (KPE) than...
-
Point-of-care ultrasound to inform antiviral treatment initiation in chronic hepatitis B virus infection in low-resource settings – the PUSH protocol
BackgroundChronic Hepatitis B (CHB) is prevalent worldwide and most related deaths occur in low-resource settings. Antiviral treatment of CHB is...
-
Risk of HCC in Patients with HBV, Role of Antiviral Treatment
Purpose of ReviewRisk prediction and reduction of hepatocellular carcinoma (HCC) in patients with chronic hepatitis B virus (HBV) infection has been...
-
Antiviral activity and mechanism of the antifungal drug, anidulafungin, suggesting its potential to promote treatment of viral diseases
BackgroundThe severe fever with thrombocytopenia syndrome disease (SFTS), caused by the novel tick-borne SFTS virus (SFTSV), was listed among the top...
-
Is antiviral treatment at the acute phase of COVID-19 effective for decreasing the risk of long-COVID? A systematic review
PurposePreliminary evidence suggests a potential effect of antiviral medication used during the acute COVID-19 phase for preventing long-COVID. This...
-
Regression in hepatic fibrosis in elderly Chinese patients with hepatitis C receiving direct-acting antiviral treatment
BackgroundPatients infected with Hepatitis C virus (HCV) are recommended to receive treatment with direct-acting antiviral agents (DAAs), which have...
-
Estimation of Intangible Costs for Factors Associated with Oral Antiviral Drugs for COVID-19 Treatment: A Conjoint Analysis in Japan
IntroductionDuring the recent coronavirus disease 2019 (COVID-19) pandemic, preferences for factors associated with vaccines have been evaluated....
-
Outcome of direct-acting antiviral treatment in patients with hepatitis C virus/hepatitis B virus coinfection
BackgroundOral direct-acting antiviral (DAA) regimens for chronic hepatitis C virus (HCV) infection have greatly improved treatment efficacy, with...
-
Correlation of host factor with virological response to direct-acting antiviral treatment in hepatitis C patients
BackgroundHepatitis C virus (HCV) infection is the global epidemic of this century, affecting almost 100 million people, and it is now the leading...
-
Effectiveness of antiviral treatment in HBeAg-negative chronic hepatitis B patients with normal or mildly elevated alanine aminotransferase: a retrospective study
BackgroundThere are inadequate data and no histological evidence regarding the effects of antiviral treatment for hepatitis B e-antigen...
-
Real-world treatment outcome with protease inhibitor direct-acting antiviral in advanced hepatitis C cirrhosis: a REAL-C study
IntroductionCurrent guidelines discourage the use of direct-acting antiviral (DAA) containing protease-inhibitor (PI) in advanced HCV cirrhosis. We...
-
Effective Analysis of Antiviral Treatment in Patients with HBeAg-Seropositive Chronic Hepatitis B with ALT < 2 Upper Limits of Normal: A Multi-center Retrospective Cohort Study
IntroductionAlthough the indications for antiviral therapy for patients with chronic hepatitis B have been gradually expanded in different...
-
Novel treatment combining antiviral and neutralizing antibody-based therapies with monitoring of spike-specific antibody and viral load for immunocompromised patients with persistent COVID-19 infection
Because prolonged viral replication of SARS-CoV-2 is increasingly being recognized among immunocompromised patients, subacute or chronic COVID-19...
-
Antiviral Treatment Options for Severe Fever with Thrombocytopenia Syndrome Infections
Severe fever with thrombocytopenia syndrome virus (SFTSV) is a tick-borne virus that produces severe fever with thrombocytopenia syndrome (SFTS). It...
-
Lower risk of hepatocellular carcinoma with tenofovir than entecavir in antiviral treatment-naïve chronic hepatitis B patients: a systematic review and meta-analysis involving 90,897 participants
Entecavir (ETV) and tenofovir disoproxil fumarate (TDF) are equally recommended as first-line treatments for antiviral treatment-naïve (ART-naïve)...
